MRK withdraws Keytruda SCLC indication in US market—(a consequence of failure of the confirmatory study, KEYNOTE-604, to show a statsig OS benefit, as reported in Jan 2020):
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.